Hayward, California-based antibiotics developer MicuRx Pharmaceuticals raised $55 million in a Series C venture capital round to fund further clinical trials in the US for its next-generation oral oxazolidinone MRX-I through to the drug’s first New Drug Application filing in China.
MicuRx Pharmaceuticals Inc.’s latest financing exercise – a Series C financing - brought it $55m which the Sino-US drug developer will use to progress its lead drug candidate, MRX-I, an oral oxazolidinone antibiotic currently in Phase III China trials.
MicuRx touts MRX-I’s oral availability and safety profile as advantages over the other drugs. MRX-I is designed to treat infections...
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
